Objectives. To determine the change in established biomarkers of cardiovascular (CV) risk, namely, total cholesterol/high-density lipoprotein cholesterol ratio (TC/HDL-C), N-terminal pro-brain natriuretic peptide (NT-proBNP) and insulin resistance (IR) in patients with early RA treated with two different treat-to-target strategies.
Introduction
Accelerated cardiovascular disease (CVD) is well recognized in established RA, with similar observations recently reported in early RA [1] . The utility of the biomarkers of CV risk used in the general population remains to be determined [2] .
Three commonly measured biomarkers are total cholesterol/high-density lipoprotein cholesterol (TC/HDL-C) [3] , the homeostasis model assessmentestimated insulin resistance (HOMA-IR) [4, 5] and N-terminal pro-brain natriuretic peptide (NT-proBNP) [6] . In RA, the levels of these biomarkers are raised [1, 7, 8] , and TC/HDL-C and NT-proBNP have been associated with future CV events [9, 10] . HOMA-IR, a measure of IR, is an independent predictor of CVD in the general population.
The effect of RA disease suppression on biomarkers of CV risk has not been extensively explored, particularly in early disease. It is clear that CV morbidity and mortality are reduced with the use of DMARDs [11] and TNF inhibitors (TNFis) [12] . DMARDS appear to reduce TC/ HDL-C [13, 14]; however, meta-analyses report conflicting results [15, 16] , suggesting a complex relationship. IR can be improved with DMARDs in established RA [17] , but the effect of TNFis are unclear [1824] . The limited data on NT-proBNP suggest improvement with TNFis [25] .
Few studies have compared the change in biomarkers of CV risk with different treatment strategies in the context of a randomized controlled trial (RCT). Cross-sectional and small open-label studies have found no differences in lipid profile when comparing TNFis with DMARDs [2628] . The Treatment of Early Aggressive RA (TEAR) study is the only previous RCT to assess change in TC/HDL-C. A similar decrease in TC/HDL-C at week 24 was observed in early RA patients randomized to MTX + etanercept, triple DMARD therapy or aggressively titrated MTX [29] . No superiority of TNFis over DMARDs was found on changes in HOMA-IR in crosssectional studies [30] ; however, one unblinded RCT of 40 early RA patients given MTX or infliximab (IFX) + MTX reported a lower fasting glucose at 12 months in the IFX arm [27] . Recent observational studies have reported up to a 50% reduction in the incidence of diabetes mellitus in RA patients treated with TNFis compared with DMARDs [31, 32] . To our knowledge, there has not been a double-blinded RCT study, to date, comparing the change in HOMA-IR with TNFis vs non-TNFis in early DMARD-naïve RA.
Our first objective was to assess the change in biomarkers of CV risk in DMARD-naïve early RA patients, treated with IFX + MTX or MTX + methylprednisolone (MP) within the framework of a RCT. Our endpoints of interest included the change in TC/HDL-C, HOMA-IR and NT-proBNP. Our secondary exploratory objective was to determine whether any change seen in biomarkers of CV risk differed depending on treatment strategy.
Methods
The IDEA study IFX as Induction therapy for Early rheumatoid Arthritis was a multicentre double-blind RCT performed within the Yorkshire network [33] , with full ethical approval to undertake the studies presented in this manuscript (RR05/7092, Eudract-2005-005013-37 and ISRCTN48638981).
The study details and results have been recently reported [33] , but in brief, consecutive DMARD-naïve patients with 312 months symptom duration meeting the 1987 ACR criteria were recruited into the study, following obtaining informed patient consent. Participants were randomized to receive either IFX + MTX or MTX and a pulse of 250 mg i.v. MP as induction therapy. A dose of 120 mg i.m. MP was given at weeks 6, 14, 22, 38, 50 and 62 if DAS >2.4. Patients were unblinded at week 26, and subsequently treatment was guided by disease activity according to a pre-determined therapeutic regime.
At baseline, weeks 26 and 78, the presence of CV comorbidity and traditional risk factors were documented in addition to disease phenotype and activity. Blood pressure, height, weight, hip and waist circumference, and the use of lipid-lowering and anti-hypertensive therapy were recorded. Patients completed the Rose Angina Questionnaire [34] and Edinburgh Claudication questionnaire [35] at baseline and week 78.
The subset of patients recruited in Leeds underwent fasting blood collection at baseline, weeks 26 and 78. Glucose, TC, HDL-C, apolipoproteins A (Apo-A) and B (Apo-B), Lipoprotein A (Lp(a)), NT-proBNP and insulin in the serum were determined. Low-density lipoproteincholesterol (LDL-C), HOMA-IR and the TC/HDL-C ratio were calculated according to known formulas (see supplementary methods, available at Rheumatology Online).
Statistical analysis
Analyses were performed in SPSS (version 21, IBM, NY, USA) and Stata (version 13.0, Statacorp, Texas, USA) (details in the supplementary section, available at Rheumatology Online). Missing data were managed using multiple imputation by chained equations.
Biomarkers HOMA and NT-proBNP were found to be highly skewed; values were ln-transformed prior to parametric analyses. The exponentiated differences between values on a log scale represent the ratio of one value to another. Therefore, changes between visits have been expressed as the ratio of the follow-up values to the baseline values, and differences between groups represent the ratio of values in the MTX + IFX group to those in the MTX + MP group.
Multiple linear regression was used to show whether changes in biomarkers differed between the treatment groups, controlling for baseline values, and then repeated, controlling for baseline BMI, ACPA positivity, glucocorticoid dose and smoking status (current vs ex-/non).
Results

Baseline characteristics
Biomarkers of CV risk data were available for 86/112 patients recruited into the Induction therapy for Early rheumatoid Arthritis study. Of these 86, 7 patients (8%) had existing CVD at baseline; 4 (5%) had ischaemic heart disease, 3 (3.5%) cerebrovascular disease and 1 (1%) peripheral vascular disease, and these were excluded from subsequent analyses (Fig. 1) .
Of the remaining 79 patients, 38 (48%) received IFX + MTX and 41 (52%) MTX + MP. Baseline clinical characteristics and biomarkers of CV risk are presented in Table 1 . When compared with subjects with no biomarker data or those excluded from the analysis due to existing CVD (n = 33 in total), those within the CV substudy were younger [mean (S.D.) age 51.6 (12.7) vs 57.3 (12.5) years, P = 0.031] and had a lower SJC44 [median (IQR) 8.0 (5.513.0) vs 12 (6.521), P = 0.034]. No differences in gender, serology or CRP were recorded.
An extreme outlier with a history of hypertension was identified on analysis of NT-proBNP (3343 pg/ml). This subject also had a low HDL-C (34.13 mg/dl), a TC/HDL-C ratio of 5.71 and a relatively high HOMA-IR (2.94). The data for NT-proBNP are presented with this patient excluded.
Relationship of biomarkers of CV risk with baseline variables
Correlation analyses at baseline revealed no association between TC/HDL-C, HOMA-IR or NT-proBNP and CRP or SJC44 (Table 2) . However, HAQ-DI correlated positively with NT-proBNP (r = 0.332, P = 0.004), and BMI correlated positively with TC/HDL-C (r = 0.312, P = 0.006) and HOMA-IR (r = 0.574, P < 0.001). No association was seen between BMI and NT-proBNP, or between waist/ hip circumference (WHR) and TC/HDL-C, HOMA-IR and NT-proBNP.
There was no difference in TC/HDL-C, HOMA-IR or NTproBNP according to RF or current smoking status at 14 (34) 10 ( 
Follow-up
Of the patients included in this substudy, 14/79 (6 IFX + MTX, 8 MTX + MP) did not complete the study treatment schedule for various reasons, including failure to suppress disease activity (37) . Three patients had missing data at baseline; data on TC/HDL-C, NT-proBNP and HOMA-IR were available for 76 patients at baseline and week 26, and 66 patients at week 78. Values of TC/HDL-C, natural log-transformed HOMA-IR and NT-proBNP, and DAS44-CRP were imputed at weeks 26 and 78, while BMI and WHR were imputed at week 78 only. In addition to baseline values of each variable, gender, smoking status, ACPA positivity and mean glucocorticoid requirement were included in the imputation models. One patient developed ischaemic heart disease by week 78, but there were no new cases of diabetes mellitus or peripheral/cerebrovascular disease.
Differences between treatment groups
Disease activity: consistent with the reported findings, DAS44-CRP in patients within the CV substudy did not differ between treatment groups at weeks 26 or 78 [adjusted mean difference À0.17 (À0.54, 0.19), t = À0.95, P = 0.345, and 0.32 (À0.10, 0.74), t = 1.50, P = 0.137, respectively].
Biomarkers: substantive reductions in all three biomarkers were observed at week 26, irrespective of treatment, with no significant differences between the groups at week 26; TC/HDL-C decreased by 0.70.9 U, HOMA-IR decreased by 2829%, while NT-proBNP decreased by 1617% (Table 3) . At week 78, TC/HDL-C continued to improve in both groups, while NT-proBNP values were similar to those at week 26. However, the IFX + MTX group showed further improvement in HOMA-IR at week 78 (by 55% relative to baseline), while there was some loss of the early week 26 improvements in HOMA-IR in the MTX + MP group. On average at week 78, IFX + MTX HOMA-IR values were 0.58 times as high as those treated with MTX + MP (P = 0.003). Findings were similar when restricted to observed data only (see supplementary Table S1 , available at Rheumatology Online). Results for HDL-C, LDL-C, Apo A and B, and Lp(a) are shown in supplementary Tables S2S6, available at Rheumatology Online.
At week 26, the proportions of patients with an at-risk ratio of TC/HDL-C were 20.1% and 13.2% in the MTX + MP and IFX + MTX groups, respectively [adjusted odds ratio (OR) = 0.89 (0.21, 3.78), t = À0.16, P = 0.876); at week 78 the proportions were 21.5% and 17.1%, respectively [adjusted OR = 1.14 (0.24, 5.28), P = 0.870]. At week 26 the proportions of patients with at-risk levels of NT-proBNP were 8.0% and 13.2% in the MTX + MP and IFX + MTX groups, respectively [adjusted OR = 0.95 (0.15, 6.14), P = 0.959]); at week 78 the proportions in the observed data were 0% and 12.9%; thus, in some of the imputed datasets (n = 5), none of the patients in the MTX + MP group had at-risk levels of NT-proBNP at week 78, causing the individual models to fail and making it impossible to obtain a combined estimate of the effect for all 20 sets. This potential difference would need to be confirmed in a future larger study. between groups was similar irrespective of ACR20 response.
Combined group analysis
Controlling for baseline values, and irrespective of treatment strategy, there was no evidence that changes in TC/ HDL-C, HOMA-IR or NT-proBNP during 78 weeks of follow-up were associated with changes in DAS44-CRP over the same period (Table 5) . However, patients achieving ACR70 responses had lower TC/HDL-C (differences between the means: 0.68 U, P = 0.012), and their HOMA-IR values were 31% lower on average (P = 0.042) than those who did not achieve a response. Change in BMI at week 78 was not associated with changes in TC-HDL-C, HOMA-IR or NT-proBNP, but HOMA-IR increased by 35.2% for each additional 10% of WHR (P = 0.033).
Use of CVD screening questionnaires
Eleven of the 76 patients who completed the Rose Angina questionnaire at baseline declared they had chest pain. However, nine patients mapped the pain to joints, and eight were thought not to have angina-related conditions when assessed by the subinvestigator. Of the 76 patients who completed the Edinburgh claudication questionnaire at baseline, 39 reported leg pain; however, 30 mapped the pain to joints and 31 were marked by the subinvestigator as not related to intermittent claudication. Similar results were seen at week 78.
Discussion
This RCT demonstrated that treatment of DMARD-naïve RA with either IFX + MTX or MTX + MP induction therapy, combined with a treat-to-target (T2T) approach, can improve biomarkers of CV risk. In addition, despite similar end-of-study disease activity levels, we demonstrated a superiority of IFX + MTX over MTX + MP in the margin of improvement in HOMA-IR, independent of BMI and IA/i.m. glucocorticoid use.
Our baseline analysis revealed no association of TC/ HDL-C with markers of disease activity, similar to reports from established RA cohorts [36] , supporting the opinion that TC/HDL-C may be more reliable in calculating longterm CV risk than other lipid measurements, such as LDL-C, which decreases with inflammation (lipid paradox). There is evidence to support the synthesis of NT-proBNP following inflammatory cytokine release [37] . We, however, failed to identify an association between NT-proBNP and inflammation or disease activity (excluding HAQ-DI); this is in contrast to several studies that included patients with longer disease durations [7, 38] . In one early RA study, NT-proBNP correlated with baseline CRP, predicting NTproBNP with repeated measures at 10 years [39] ; however, CV co-morbidity data was not collected, limiting its application to those without clinical CVD. Given that NT-proBNP reflects the final stages in the pathogenesis of CVD, its utility in early RA could be limited. We found no evidence to support higher NT-proBNP levels in early RA.
An improvement was seen in TC/HDL-C and IR in both treatment groups after 26 weeks, which was sustained at week 78. The improvement in TC/HDL-C occurred due to an increase in both HDL-C and LDL-C (supplementary  Tables S5 and S6 , available at Rheumatology Online). Similar magnitudes of change have been reported previously [13] . The effect of therapy on HOMA-IR has been less well studied [40] , with most reporting the effect of TNFis alone, involving small established RA cohorts [19, 20] or short-term follow-up [18] . Our study provides valuable longer-term data. NT-proBNP also improved at weeks 26 and 78, although the change was not statistically significant at the latter time point. The prospective studies reporting improvement in NT-proBNP with TNFis are in established RA cohorts with mean disease durations of at least 7 years and higher baseline NT-proBNP values [25, 41, 42] , with perhaps a greater cumulative burden of disease. Longer-term follow-up data is now required from inception cohorts.
We determined that meeting ACR70 response criteria was associated with lower values of TC/HDL-C and HOMA-IR at week 78, suggesting that aggressive treatment can lead to a more favourable lipid profile and improved IR in the long term. Our findings are supported by Park et al. [8] , who showed that improvement in HDL-C and LDL-C/HDL-C in 42 early RA patients after treatment with glucocorticoids and DMARDs for 1 year was significantly improved in ACR20 responders compared with in non-responders. They did not report the results for TC/ HDL-C. The Combinatietherapie Bij Reumatoide Artritis [20] . We found no difference in improvement in TC/HDL-C between the treatment regimes, in line with previous cross-sectional studies [26, 28] and the TEAR trial, where a similar fall in non-fasting TC/HDL-C was seen in all treatment arms [29] . Unlike our study, however, it is not clear whether the disease activity was similar across the groups, making comparisons between therapeutic regimes difficult. NT-proBNP did not differ between the groups, but longer follow-up may be needed to identify any differences.
The major finding from our study was that TNFis appear to provide additional benefit in the improvement in IR above the use of MTX + MP when using a T2T approach. IR improved by nearly half as much in comparison. This is an important finding, because although patients with RA do not appear to have a greater prevalence of diabetes mellitus [43] (the prevalence of diabetes mellitus in our study was similar to that found in the general population [44] ), patients with RA are at higher risk of IR. This is the first RCT, to our knowledge, to compare the change in HOMA-IR between treatment regimes in early RA. This supports the emerging evidence that TNFis therapy improves insulin sensitivity and reduces IR in RA [40] . One cross-sectional study reported no difference in HOMA-IR in 37 RA patients treated with either (i) TNFis, (ii) MTX or (iii) no treatment, but disease durations and activity varied across the groups [30] . In the open-label study by Tam et al. [27] , the higher fasting plasma glucose in the non-TNFis arm could be explained a higher proportion of patients in the TNFis group achieving remission; with the difference seen reflecting the degree of systemic inflammation. In our study, disease activity at week 78 was similar in both treatment groups, and controlling for i.m. glucocorticoid use produced comparable results.
The metabolic role of adipose tissue may underlie our observations. Visceral (central) obesity is associated with a chronic, low-grade inflammatory state (including TNF production) and has been implicated in the development of IR [45] . Adipokines secreted by adipose tissue play a significant role in the development of metabolic syndrome and were recently recognized as novel biomarkers and regulators of metabolic syndrome [46] . We observed that HOMA-IR was positively correlated with BMI. Central abdominal rather than gluteo-femoral adipose tissue has been shown to secrete higher levels of inflammatory cytokines [47] , strengthening the argument that fat distribution (i.e. WHR) is important in determining future CV risk. We found no relationship between WHR and baseline HOMA-IR, although an increase in WHR over time was associated with an increasing IR.
The use of the Rose Angina and Edinburgh Claudication questionnaires proved unreliable in our study; primarily because synovitis led to many false-positive results. Although both validated screening methods for CVD in the general population, their use may be limited in RA, and more specific tools are required.
This study has several limitations. First, it was not designed nor powered to investigate the change in biomarkers of CV risk. However, we feel that the magnitude of difference between the treatment groups for IR is an important finding and should encourage larger, more focused studies. Second, only a subset of patients had samples collected for biomarker analysis due to the practicalities of sample processing and storage in peripheral hospitals. However, we would argue that no selection bias was encountered because each hospital cohort was independently randomized. Finally, we recognize that longterm data is required to validate the improvement in lipid profiles and IR found, and to detect any reduction in CV outcomes and diabetes mellitus. This data would also help determine the biomarker that best predicts CVD in the context of systemic inflammation.
In conclusion, this study confirms the improvement of soluble biomarkers of CV risk with suppression of disease activity in early RA using a T2T approach. TNFis appeared to show additional benefit over MTX + MP in measures of IR. This raises the question of whether TNFis may confer additional protection in the prevention of CVD over and above the suppression of inflammation. Our conclusions should encourage similar, but more long-term studies, employing overt CV outcomes, or validated surrogate measures of CVD (in the general population), such as arterial stiffness or carotid intima-media thickness, as end-points. 
